Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5088603
Max Phase: Preclinical
Molecular Formula: C45H55FN12O7
Molecular Weight: 895.01
Molecule Type: Unknown
Associated Items:
ID: ALA5088603
Max Phase: Preclinical
Molecular Formula: C45H55FN12O7
Molecular Weight: 895.01
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)n1cnc2c(NCc3nc4cc(F)c(NCCCCCCCCCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)cc4[nH]3)nc(N3CCOCC3)nc21
Standard InChI: InChI=1S/C45H55FN12O7/c1-27(2)57-26-50-39-40(54-45(55-41(39)57)56-18-20-64-21-19-56)49-24-35-51-31-22-29(46)30(23-32(31)52-35)47-16-9-7-5-3-4-6-8-10-17-48-37(60)25-65-34-13-11-12-28-38(34)44(63)58(43(28)62)33-14-15-36(59)53-42(33)61/h11-13,22-23,26-27,33,47H,3-10,14-21,24-25H2,1-2H3,(H,48,60)(H,51,52)(H,49,54,55)(H,53,59,61)
Standard InChI Key: NKPHVUBPIOSUEX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 895.01 | Molecular Weight (Monoisotopic): 894.4301 | AlogP: 5.00 | #Rotatable Bonds: 21 |
Polar Surface Area: 230.69 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.50 | CX Basic pKa: 6.20 | CX LogP: 3.86 | CX LogD: 3.85 |
Aromatic Rings: 5 | Heavy Atoms: 65 | QED Weighted: 0.05 | Np Likeness Score: -1.19 |
1. Niu T, Li K, Jiang L, Zhou Z, Hong J, Chen X, Dong X, He Q, Cao J, Yang B, Zhu CL.. (2022) Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor., 228 [PMID:34864331] [10.1016/j.ejmech.2021.114012] |
Source(1):